Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision therapeutics in oncology (CRB-701 Nectin-4 ADC for HNSCC and cervical cancer; CRB-601 anti-αvβ8 antibody) and obesity (CRB-913 oral CB1 inverse agonist), funded primarily through public equity offerings and pre-revenue.
- Company typePublic
- Founded2014
- HeadquartersNorwood, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Corbus Pharmaceuticals does
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered at 500 River Ridge Drive, Norwood, Massachusetts, publicly traded on NASDAQ under ticker CRBP with a market capitalization of approximately $137-178 million. The company employs 51-100 staff and is developing precision therapeutics across two distinct therapeutic verticals: oncology and obesity/metabolic disease. Corbus's core pipeline comprises three clinical-stage assets: CRB-701, a next-generation Nectin-4-targeting antibody drug conjugate (ADC) using site-specific conjugation and a novel linker to deliver monomethyl auristatin E (MMAE), licensed from CSPC Megalith Biopharmaceutical for head and neck squamous cell carcinoma (HNSCC) and cervical cancer indications; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity representing a non-incretin, non-GLP-1 mechanism, licensed from Jenrin Discovery; and CRB-601, an anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGF-β in the tumor microenvironment, licensed from the University of California San Francisco. The company previously developed lenabasum, a CB2 agonist for inflammatory-fibrotic conditions, but discontinued the program after Phase 3 failures in systemic sclerosis (2020) and dermatomyositis.
Corbus operates a pre-revenue business model funded almost entirely by capital markets. The company has raised approximately $169.5 million through two recent public equity offerings ($94.5M in February 2024 at $19.00/share and ~$75M in October 2025), supplementing earlier financings totaling over $300 million since 2014. As of Q1 2026, the company reported $138.2 million in cash, cash equivalents, and investments, with quarterly operating expenses of approximately $24.3 million and net losses of $20-23 million, providing a runway into 2028. The go-to-market approach contemplates future product sales upon regulatory approval or out-licensing to larger pharmaceutical partners, with the existing CSPC license representing a precedent for such transactions. CRB-701 has received FDA Fast Track designation in both HNSCC and cervical cancer indications, supporting a registrational study path for second-line HNSCC.
The company's competitive positioning rests on differentiated drug design rather than AI or digital capabilities. CRB-701's site-specific conjugation technology aims to deliver an improved therapeutic index versus PADCEV (the incumbent Nectin-4 ADC from Pfizer/Astellas), while CRB-913's peripheral restriction targets an obesity mechanism orthogonal to GLP-1 receptor agonists. Corbus engages institutional investors through conferences (RBC, Jefferies, BTIG) and the medical community through major oncology venues (ASCO 2026, ESMO 2025), supplemented by Key Opinion Leader events with leading HNSCC experts. The leadership team comprises CEO Yuval Cohen, CFO Sean Moran, and recently appointed CBO Nishant Saxena (ex-Evercore Managing Director), with a board chaired by Rachelle Jacques and including Brent Pfeiffenberger (CEO of Century Therapeutics, ex-BMS Head of U.S. Oncology).
Corbus Pharmaceuticals firmographics
Firmographics- Name
- Corbus Pharmaceuticals
- Legal name
- Corbus Pharmaceuticals Holdings, Inc.
- Website
- https://corbuspharma.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision therapeutics in oncology (CRB-701 Nectin-4 ADC for HNSCC and cervical cancer; CRB-601 anti-αvβ8 antibody) and obesity (CRB-913 oral CB1 inverse agonist), funded primarily through public equity offerings and pre-revenue.
- Ownership category
- akta.pro rank
Corbus Pharmaceuticals industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Corbus Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Norwood
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Corbus Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage company developing pipeline of drug candidates (CRB-701, CRB-913, CRB-601) for oncology and obesity indications. Revenue will be generated through product sales upon regulatory approval or through licensing/partnership agreements.
- Licensing and Partnership Deals: Company may enter into licensing agreements for drug candidates, such as the CRB-701 license from CSPC and potential future partnerships to fund development and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Corbus Pharmaceuticals product offering
Product offeringCore offering
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drug candidates for precision oncology and obesity. Its core pipeline consists of CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company licenses drug candidates from partners (CSPC, UCSF, Jenrin Discovery) and advances them through clinical trials toward regulatory approval.
Product overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing targeted therapies in precision oncology and obesity. The company's core product portfolio includes CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral CB1 inverse agonist for obesity with a non-incretin mechanism; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company previously developed Lenabasum (CB2 agonist) but discontinued clinical development after Phase 3 trial failures. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. and CRB-601 is in-licensed from UCSF. CRB-913 was developed internally from the company's endocannabinoid platform.
Differentiator
Problem solved
Functional benefit
Products and services
- CRB-701 Next-generation antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Licensed from CSPC Megalith Biopharmaceutical Co., Ltd., with FDA Fast Track designation for both cancer types. Demonstrated 42.9% ORR in second-line OPSCC and 34.4% in second-line cervical cancer at 3.6 mg/kg dose.
- CRB-913 Highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity, representing a non-GLP-1 and non-incretin mechanism of action for weight loss and long-term weight management. Licensed from Jenrin Discovery, LLC. CANYON-1 Phase 1b trial testing three oral dose cohorts (20mg, 40mg, and 60mg daily).
- CRB-601 Anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGFβ within the tumor microenvironment for treatment of solid tumors. Being developed in combination with checkpoint inhibitors. Licensed from UCSF with FDA IND clearance.
Quantifiable outcome
- 42.9% objective response rate in second-line oropharyngeal squamous cell carcinoma at 3.6 mg/kg dose
- +4 more outcomes
Companies that use Corbus Pharmaceuticals
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Corbus Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Corbus Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- CSPC Megalith Biopharmaceutical Co., Ltd. (CSPC)coreExclusive licensing agreement granting Corbus rights to develop and commercialize CRB-701 (Nectin-4 targeting ADC) in the United States, Canada, European Union, United Kingdom, and Australia for all oncology indications. CSPC retains rights in China and other territories.
- University of California, San Francisco (UCSF)coreExclusive worldwide license to patent applications relating to humanized antibodies against integrin αvβ8 (CRB-601), including antibody for diagnostic use and related know-how and materials.
- Jenrin Discovery, LLCcoreExclusive worldwide license to develop and market cannabinoid compounds (including CRB-913) covered by Jenrin patents for obesity, diabetes, hepatic disorders, and cardiometabolic disorders.
- Kaken Pharmaceutical Co., Ltd.minorStrategic collaboration to develop and commercialize lenabasum in Japan for systemic sclerosis and dermatomyositis.
Scale indicators5 records
Recent moves10 records
Expansion highlights6 records
Corbus Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- ImmunoGen (AbbVie): Pioneer in ADC technology with approved ELAHERE (mirvetuximab). Acquired by AbbVie in 2024, illustrating the strategic exit path for differentiated ADC developers and a relevant benchmark for ADC-focused clinical-stage companies.
- Eli Lilly: Markets Mounjaro/Zepbound (tirzepatide), the dominant GLP-1 obesity therapy. Defines the standard of care that CRB-913's non-incretin CB1 mechanism must differentiate against in the obesity indication.
- Pfizer (Seagen): Markets PADCEV (enfortumab vedotin), the only approved Nectin-4 targeting ADC. Direct mechanistic competitor to Corbus's lead asset CRB-701 in HNSCC and cervical cancer, and validates the Nectin-4 ADC commercial opportunity at scale.
- Novo Nordisk: Markets Wegovy/Ozempic (semaglutide), the established GLP-1 obesity therapy. Sets the efficacy and safety benchmark against which any non-GLP-1 obesity asset like CRB-913 must demonstrate meaningful clinical differentiation.
- Daiichi Sankyo: Global leader in ADC technology (DXd platform behind Enhertu and ifinatamab deruxtecan, a Nectin-4 ADC partnered with Merck). Comparable pipeline of oncology ADCs and a benchmark for next-generation site-specific linker technology that Corbus is emulating.
Emerging players
- Century Therapeutics: Clinical-stage oncology biotech led by Brent Pfeiffenberger (Corbus board member and former BMS oncology SVP). Comparable as a small-cap, public, clinical-stage oncology company developing novel cell therapy and targeted oncology approaches.
- Mythic Therapeutics: Clinical-stage biotech developing antibody therapeutics for solid tumors using proprietary technology to address resistance to current therapies. Comparable as a small-cap precision oncology developer leveraging novel antibody engineering approaches.
Direct peers
- Mersana Therapeutics: Clinical-stage oncology biotech developing next-generation ADCs with proprietary linker and payload platforms. Closely comparable to Corbus as a small-cap, pipeline-focused ADC developer advancing differentiated ADC chemistry toward registrational studies.
Others
- CSPC Megalith Biopharmaceutical: Licensor of CRB-701 to Corbus. Retains China and other territorial rights and continues to develop the parent Nectin-4 ADC program, making it the most directly connected party on asset economics, manufacturing, and global development strategy.
Regional players
- Krystal Biotech: Commercial-stage gene therapy biotech whose former subsidiary Jeune Aesthetics employed Corbus CBO Nishant Saxena. Provides a comparable public, US-based small-cap biotech archetype that successfully transitioned from clinical to commercial stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Corbus Pharmaceuticals social profiles
Digital presenceCorbus Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corbus Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Corbus Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds13 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corbus Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corbus Pharmaceuticals
What does Corbus Pharmaceuticals do?
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drug candidates for precision oncology and obesity. Its core pipeline consists of CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company licenses drug candidates from partners (CSPC, UCSF, Jenrin Discovery) and advances them through clinical trials toward regulatory approval.
Is Corbus Pharmaceuticals a public or private company?
Corbus Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Corbus Pharmaceuticals founded?
Corbus Pharmaceuticals was founded in 2014. It employs 11 to 50 people.
Where is Corbus Pharmaceuticals based?
Corbus Pharmaceuticals is headquartered in Norwood, United States, in the North America region.
How does Corbus Pharmaceuticals make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are licensing and Partnership Deals.
Who are Corbus Pharmaceuticals's main competitors?
Broad incumbents on record are ImmunoGen (AbbVie), Eli Lilly, Pfizer (Seagen), Novo Nordisk and Daiichi Sankyo. Emerging players are Century Therapeutics and Mythic Therapeutics. Mersana Therapeutics is listed as a direct peer. CSPC Megalith Biopharmaceutical is listed as an others. Krystal Biotech is listed as a regional player.
Does Corbus Pharmaceuticals have an API?
No public API is recorded for Corbus Pharmaceuticals.
What industry is Corbus Pharmaceuticals in?
Corbus Pharmaceuticals's product category is Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 541714 and its SIC code is 2834.